Multidisciplinary management of osteosarcoma: Experience in Hong Kong

Pediatric Hematology and Oncology

Volumn 15, Issue 3, 1998, Pages 229-236

  Kwong, D L W ^a,b   Ha, S Y ^a   Chau, K Y ^b   Choi, P H K ^c   Chan, G C F ^a   Kwong, P W K ^a   Lau, Y L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Multidisciplianry care; Osteosarcoma; Pediatric

Indexed keywords

METHOTREXATE;

ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HONG KONG; HUMAN; LIMB AMPUTATION; LIMB SALVAGE; MALE; OSTEOSARCOMA; TREATMENT OUTCOME;

EID: 0031842046     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.3109/08880019809028789     Document Type: Article

References (16)

1. Marcove RC, Mike V, Hajek JV, Levin AG, Hutter RY. Osteogenic sarcoma under the age of twenty-one. J Bone Joint Surg. 1970;52:411-423.
2. Classer DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma. Cancer. 1992;69:698-708.
3. Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma. Therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990;8:1988-1997.
4. Bramwell VHC, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992;10:1579-1591.
5. Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop. 1991;270:8-14.
6. Lane JM, Hurson B, Boland PJ, Classer DB. Osteogenic sarcoma. Clin Orthop. 1986;204:93-110.
7. Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106:55-67.
8. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection and prosthetic bone replacement. Arch Pathol Lab Med. 1977;101:14-18.
9. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221-1230.
10. Marina NM, Pratt CB, Rao BN, Shema SJ, Meyer WH. Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer. 1992;70:2722-2727.
11. Parkin DM, Stiller CA, Nectoux J. International variations in the incidence of childhood bone tumours. Int J Cancer. 1993;53:371-376.
12. Delepine N, Delepine G, Jasmin C, Desbois JC, Cornille H, Mathe G. Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcomas. Biomed Pharmacother. 1988;42:257-262.
13. Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol. 1994;12:1443-1451.
14. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423-431.
15. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomised cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6:329-337.
16. Meyers PA, Heller G, Healey J, et al. Chemotherapy for non-metastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.